면역글로불린 제제 시장(2024-2028년)

The immunoglobulin products market is forecasted to grow by USD 9699.84 mn during 2023-2028, accelerating at a CAGR of 10.11% during the forecast period. The report on the immunoglobulin products market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by recent immunoglobulin product developments, rising prevalence of immunodeficiency disorders and autoimmune diseases, and growing geriatric population.

Technavio's immunoglobulin products market is segmented as below:

By Product

• IgG
• IgA
• IgM
• IgD
• IgE

By Route Of Administration

• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the advancements in biotechnology and manufacturing processes as one of the prime reasons driving the immunoglobulin products market growth during the next few years. Also, increasing adoption of subcutaneous administration and growing focus on personalized medicine will lead to sizable demand in the market.

The report on the immunoglobulin products market covers the following areas:

• Immunoglobulin products market sizing
• Immunoglobulin products market forecast
• Immunoglobulin products market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading immunoglobulin products market vendors that include ADMA Biologics Inc., Bio Products Laboratory Ltd., Biocon Ltd., CSL Ltd., GC Biopharma corp. , Grifols SA, Kedrion S.p.A, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Serum Institute of India Pvt. Ltd., Shanghai RAAS Blood Products Co. Ltd., Taibang Biological Group Co. Ltd., Taj Pharmaceuticals Ltd., and Takeda Pharmaceutical Co. Ltd.. Also, the immunoglobulin products market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global immunoglobulin products market 2018 - 2022
• 4.2 Product Segment Analysis 2018 - 2022
• 4.3 Route of Administration Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Product

• 6.1 Market segments
• 6.2 Comparison by Product
• 6.3 IgG - Market size and forecast 2023-2028
• 6.4 IgA - Market size and forecast 2023-2028
• 6.5 IgM - Market size and forecast 2023-2028
• 6.6 IgD - Market size and forecast 2023-2028
• 6.7 IgE - Market size and forecast 2023-2028
• 6.8 Market opportunity by Product

7 Market Segmentation by Route of Administration

• 7.1 Market segments
• 7.2 Comparison by Route of Administration
• 7.3 Intravenous (IV) - Market size and forecast 2023-2028
• 7.4 Subcutaneous (SC) - Market size and forecast 2023-2028
• 7.5 Intramuscular (IM) - Market size and forecast 2023-2028
• 7.6 Market opportunity by Route of Administration

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 China - Market size and forecast 2023-2028
• 9.9 Germany - Market size and forecast 2023-2028
• 9.10 UK - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 ADMA Biologics Inc.
• 12.4 Bio Products Laboratory Ltd.
• 12.5 Biocon Ltd.
• 12.6 CSL Ltd.
• 12.7 GC Biopharma corp.
• 12.8 Grifols SA
• 12.9 Kedrion S.p.A
• 12.10 LFB SA
• 12.11 Novartis AG
• 12.12 Octapharma AG
• 12.13 Pfizer Inc.
• 12.14 Serum Institute of India Pvt. Ltd.
• 12.15 Shanghai RAAS Blood Products Co. Ltd.
• 12.16 Taibang Biological Group Co. Ltd.
• 12.17 Taj Pharmaceuticals Ltd.
• 12.18 Takeda Pharmaceutical Co. Ltd.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations